Orchestra BioMed Holdings, Inc. (OBIO) shareholders
Close on Nov 17, 2026Market cap $418.93MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong Joint filing with RTW Investments, LP (19.20%), RTW Master Fund, Ltd. (9.60%) and 1 more | 11,942,394 | 19.20% | 13D (active) amendment | Apr 27, 2026 |
| Covidien Group S.a.r.l. Joint filing with Medtronic plc (17.80%) | 10,078,625 | 17.80% | 13G (passive) amendment | Dec 31, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong (15.40%), RTW Master Fund, Ltd. (8.10%) and 1 more | 8,306,063 | 15.40% | 13D (active) amendment | Aug 4, 2025 |
| Roderick Wong, M.D. Joint filing with RTW Investments, LP (21.70%), RTW Master Fund, Ltd. (11.50%) and 1 more | 8,306,063 | 21.70% | 13D (active) amendment | Apr 29, 2025 |
| Medtronic plc Joint filing with Covidien Group S.a.r.l. (15.40%) | 5,868,916 | 15.40% | 13G (passive) amendment | Dec 31, 2024 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%) | 5,679,480 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Dana Lorenzo Joint filing with Tasso Partners, LLC (5.00%) | 3,098,592 | 5.50% | 13G (passive) | Nov 15, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rtw Investments, LP | 9,556,063 | 15.90% | $41.23M | +1,250,000 | 0.35% |
| Perceptive Advisors LLC | 5,037,906 | 8.38% | $21.74M | – | 0.33% |
| BlackRock, Inc. | 2,510,387 | 4.18% | $10.83M | +1,874,673 | 0.00% |
| Vanguard Capital Management LLC | 2,022,916 | 3.37% | $8.73M | −181,403 | 0.00% |
| Geode Capital Management, LLC | 1,007,908 | 1.68% | $4.35M | +522,416 | 0.00% |
| Alyeska Investment Group, L.P. | 1,000,000 | 1.66% | $4.32M | – | 0.01% |
| Propel Bio Management, LLC | 896,701 | 1.49% | $3.87M | – | 2.02% |
| UBS Asset Management Americas Inc | 642,154 | 1.07% | $2.77M | New | 0.00% |
| State Street Corp | 516,050 | 0.86% | $2.23M | +346,640 | 0.00% |
| Rice Hall James & Associates, LLC | 424,000 | 0.71% | $1.83M | +404,999 | 0.09% |
| Charles Schwab Investment Management Inc | 349,544 | 0.58% | $1.51M | +84,045 | 0.00% |
| Northern Trust Corp | 343,640 | 0.57% | $1.48M | +225,366 | 0.00% |
| UBS Group AG | 325,773 | 0.54% | $1.41M | +275,463 | 0.00% |
| Vanguard Fiduciary Trust Co | 292,253 | 0.49% | $1.26M | +57,039 | 0.00% |
| Vanguard Portfolio Management LLC | 274,973 | 0.46% | $1.19M | New | 0.00% |
| Knott David M Jr | 253,651 | 0.42% | $1.09M | – | 0.58% |
| Flat Footed LLC | 251,372 | 0.42% | $1.08M | New | 0.08% |
| Simplify Asset Management Inc. | 219,387 | 0.37% | $946.66K | – | 0.01% |
| Goldman Sachs Group Inc | 179,606 | 0.30% | $775.00K | +24,364 | 0.00% |
| DAFNA Capital Management LLC | 126,841 | 0.21% | $547.32K | – | 0.10% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 77 | 28M | 46.1% | 25 / 22 | 15 / 13 | 7M | 2M |
| Q1 2026 | 65 | 23M | 38.4% | 19 / 23 | 14 / 16 | 5M | 2M |
| Q4 2025 | 63 | 22M | 36.1% | 21 / 17 | 14 / 5 | 2M | 3M |
| Q3 2025 | 52 | 23M | 38.1% | 10 / 16 | 17 / 17 | 5M | 1M |
| Q2 2025 | 59 | 18M | 30.2% | 22 / 14 | 16 / 19 | 2M | 3M |
| Q1 2025 | 56 | 19M | 31.6% | 7 / 16 | 18 / 4 | 0M | 0M |
| Q4 2024 | 54 | 19M | 32.0% | 10 / 26 | 7 / 4 | 1M | 0M |
| Q3 2024 | 48 | 19M | 31.7% | 7 / 20 | 10 / 5 | 7M | 0M |
| Q2 2024 | 47 | 14M | 23.7% | 8 / 22 | 8 / 4 | 1M | 0M |
| Q1 2024 | 43 | 13M | 22.3% | 5 / 14 | 16 / 1 | 0M | 0M |
| Q4 2023 | 39 | 13M | 22.1% | 2 / 19 | 7 / 5 | 0M | 0M |
| Q3 2023 | 42 | 13M | 21.8% | 8 / 23 | 6 / 5 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
55 funds held OBIO in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of OBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,470,063 | 2.45% | $6.34M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 830,752 | 1.38% | $3.58M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 498,632 | 0.83% | $2.15M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 428,758 | 0.71% | $1.71M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 374,286 | 0.62% | $1.62M | 0.01% | Jun 30, 2026 |
| Simplify Propel Opportunities ETF | 219,387 | 0.37% | $946.65K | 1.23% | Jun 30, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 206,130 | 0.34% | $805.97K | 0.01% | May 29, 2026 |
| Fidelity Extended Market Index Fund | 205,715 | 0.34% | $804.35K | 0.00% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 178,322 | 0.30% | $697.24K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 133,768 | 0.22% | $577.21K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 97,254 | 0.16% | $387.07K | 0.01% | Jul 31, 2026 |
| Clearwater Select Equity Fund | 86,424 | 0.14% | $372.92K | 0.07% | Jun 30, 2026 |
| Master Small Cap Index Series | 74,501 | 0.12% | $321.47K | 0.01% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 73,500 | 0.12% | $317.15K | 0.21% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 72,838 | 0.12% | $284.80K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| David P. Hochman | See Remarks, Director | 1,514,519 | 2.52% | Nov 9, 2026 |
| Darren Sherman | See Remarks, Director | 1,106,402 | 1.84% | Nov 3, 2026 |
| Andrew Lawrence Taylor | Chief Financial Officer | 590,989 | 0.98% | Nov 9, 2026 |
| Joshua Aiello | Principal Accounting Officer | 18,441 | 0.03% | Aug 28, 2026 |
| Eric S. Fain | Director | 127,130 | 0.21% | Nov 9, 2026 |
| David Pacitti | Director | 74,750 | 0.12% | Nov 9, 2026 |
| John Prosper Mack | Director | 66,544 | 0.11% | Aug 14, 2026 |
| Chris Cleary | Director | 29,153 | 0.05% | Aug 14, 2026 |
| Pamela Ann Connealy | Director | 66,038 | 0.11% | Jun 25, 2026 |
| Jason Aryeh | Director | 118,118 | 0.20% | Jun 25, 2026 |
| Rtw Investments, Lp | 10% owner | 10,756,063 | 17.90% | Nov 12, 2026 |
| Roderick Wong | 10% owner | 8,306,063 | 13.82% | Nov 12, 2026 |
| Joseph Edelman | 10% owner | – | – | Aug 5, 2025 |
| Life Sciences Master Fund Ltd Perceptive | 10% owner | 5,292,556 | 8.81% | Aug 5, 2025 |
| Advisors Llc Perceptive | 10% owner | – | – | Aug 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Rtw Investments, Lp 10% owner | Nov 9, 2026 | Buy | +1,200,000 | $5.00 | $6.00M | 10,756,063 |
| Eric S. Fain Director | Nov 9, 2026 | Buy | +20,000 | $5.00 | $100.00K | 119,630 |
| David Pacitti Director | Nov 9, 2026 | Buy | +20,000 | $5.00 | $100.00K | 74,750 |
| David P. Hochman See Remarks, Director | Nov 9, 2026 | Buy | +5,000 | $5.00 | $25.00K | 437,916 |
| Andrew Lawrence Taylor Chief Financial Officer | Nov 9, 2026 | Buy | +1,000 | $5.00 | $5.00K | 590,989 |
| Darren Sherman See Remarks, Director | Nov 2, 2026 | Sale(10b5-1 plan) | −15,000 | $5.74 | $86.10K | 1,104,402 |
| Darren Sherman See Remarks, Director | Oct 1, 2026 | Sale(10b5-1 plan) | −15,000 | $6.36 | $95.40K | 1,119,402 |
| David P. Hochman See Remarks, Director | Sep 10, 2026 | Tax withholding | −3,283 | $5.81 | $19.07K | 1,067,463 |
| David P. Hochman See Remarks, Director | Sep 10, 2026 | Tax withholding | −3,283 | $5.81 | $19.07K | 432,916 |
| David P. Hochman See Remarks, Director | Sep 3, 2026 | Buy | +10,000 | $4.79 | $47.90K | 1,070,746 |
| Darren Sherman See Remarks, Director | Sep 1, 2026 | Sale(10b5-1 plan) | −15,000 | $4.94 | $74.10K | 1,134,402 |
| Joshua Aiello Principal Accounting Officer | Aug 26, 2026 | Tax withholding | −203 | $5.26 | $1.07K | 18,441 |
| Andrew Lawrence Taylor Chief Financial Officer | Aug 26, 2026 | Tax withholding | −3,076 | $5.26 | $16.18K | 589,989 |
| Darren Sherman See Remarks, Director | Aug 26, 2026 | Buy | +2,000 | $5.33 | $10.66K | 2,000 |
| Darren Sherman See Remarks, Director | Aug 26, 2026 | Tax withholding | −4,925 | $5.26 | $25.91K | 1,149,402 |
| John Prosper Mack Director | Aug 12, 2026 | Tax withholding | −4,885 | $4.42 | $21.59K | 66,544 |
| Eric S. Fain Director | Aug 12, 2026 | Tax withholding | −5,145 | $4.42 | $22.74K | 99,630 |
| Chris Cleary Director | Aug 12, 2026 | Tax withholding | −4,238 | $4.42 | $18.73K | 29,153 |
| David Pacitti Director | Aug 12, 2026 | Tax withholding | −3,761 | $4.42 | $16.62K | 54,750 |
| Darren Sherman See Remarks, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −15,000 | $4.09 | $61.35K | 1,154,327 |
| Darren Sherman See Remarks, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −15,000 | $4.27 | $64.05K | 1,169,327 |
| John Prosper Mack Director | Jun 24, 2026 | Tax withholding | −3,510 | – | – | 71,429 |
| David Pacitti Director | Jun 24, 2026 | Tax withholding | −3,784 | – | – | 58,511 |
| Eric S. Fain Director | Jun 24, 2026 | Tax withholding | −4,261 | – | – | 104,775 |
| Chris Cleary Director | Jun 24, 2026 | Tax withholding | −3,510 | – | – | 33,391 |
| John Prosper Mack Director | Jun 23, 2026 | Award | +34,653 | – | – | 74,939 |
| David Pacitti Director | Jun 23, 2026 | Award | +17,327 | – | – | 62,295 |
| Eric S. Fain Director | Jun 23, 2026 | Award | +17,327 | – | – | 109,036 |
| Pamela Ann Connealy Director | Jun 23, 2026 | Award | +17,327 | – | – | 66,038 |
| Andrew Lawrence Taylor Chief Financial Officer | Jun 10, 2026 | Tax withholding | −36,352 | $4.02 | $146.14K | 593,065 |
| David P. Hochman See Remarks, Director | Jun 10, 2026 | Tax withholding | −3,283 | $4.02 | $13.20K | 1,060,746 |
| David P. Hochman See Remarks, Director | Jun 10, 2026 | Tax withholding | −3,283 | $4.02 | $13.20K | 436,199 |
| Darren Sherman See Remarks, Director | Jun 1, 2026 | Sale(10b5-1 plan) | −15,000 | $3.87 | $58.05K | 1,184,327 |
| David P. Hochman See Remarks, Director | Jun 1, 2026 | Buy | +5,000 | $3.83 | $19.15K | 1,064,029 |
| Andrew Lawrence Taylor Chief Financial Officer | May 28, 2026 | Tax withholding | −3,076 | $3.98 | $12.24K | 629,417 |
| Darren Sherman See Remarks, Director | May 28, 2026 | Tax withholding | −4,925 | $3.98 | $19.60K | 1,199,327 |
| Jason Aryeh Director | May 18, 2026 | Buy | +665 | $3.75 | $2.49K | 118,118 |
| David P. Hochman See Remarks, Director | May 15, 2026 | Buy | +5,000 | $3.77 | $18.85K | 1,059,029 |
| Jason Aryeh Director | May 15, 2026 | Buy | +8,971 | $3.90 | $34.99K | 117,453 |
| Eric S. Fain Director | May 14, 2026 | Buy | +20,000 | $4.13 | $82.60K | 91,709 |
| Rtw Investments, Lp 10% owner | Apr 27, 2026 | Sale | −32 | $4.13 | $132 | 9,556,063 |
| Rtw Investments, Lp 10% owner | Apr 27, 2026 | Option exercise | +1,250,032 | – | – | 9,556,095 |
| Darren Sherman See Remarks, Director | Mar 25, 2026 | Tax withholding | −33,317 | $4.57 | $152.26K | 1,204,252 |
| Joshua Aiello Principal Accounting Officer | Mar 25, 2026 | Tax withholding | −241 | $4.57 | $1.10K | 18,644 |
| David P. Hochman See Remarks, Director | Mar 25, 2026 | Tax withholding | −32,438 | $4.57 | $148.24K | 1,054,029 |
| David P. Hochman See Remarks, Director | Mar 13, 2026 | Buy | +10,000 | $4.29 | $42.90K | 1,086,467 |
| Andrew Lawrence Taylor Chief Financial Officer | Feb 12, 2026 | Award | +181,000 | – | – | 632,493 |
| David P. Hochman See Remarks, Director | Feb 12, 2026 | Award | +504,000 | – | – | 1,076,467 |
| Darren Sherman See Remarks, Director | Feb 12, 2026 | Award | +397,000 | – | – | 1,237,569 |
| Chris Cleary Director | Feb 5, 2026 | Tax withholding | −676 | $3.71 | $2.51K | 36,901 |
| Darren Sherman See Remarks, Director | Jan 2, 2026 | Tax withholding | −5,588 | $4.31 | $24.08K | 840,569 |
| Andrew Lawrence Taylor Chief Financial Officer | Jan 2, 2026 | Tax withholding | −3,452 | $4.31 | $14.88K | 451,493 |
| Joshua Aiello Principal Accounting Officer | Jan 2, 2026 | Tax withholding | −241 | $4.31 | $1.04K | 18,885 |
| Andrew Lawrence Taylor Chief Financial Officer | Dec 10, 2025 | Tax withholding | −8,670 | $4.67 | $40.49K | 454,945 |
| David P. Hochman See Remarks, Director | Dec 10, 2025 | Tax withholding | −3,283 | $4.67 | $15.33K | 439,482 |
| David P. Hochman See Remarks, Director | Dec 10, 2025 | Tax withholding | −40,355 | $4.67 | $188.46K | 572,467 |
| Andrew Lawrence Taylor Chief Financial Officer | Nov 25, 2025 | Tax withholding | −3,071 | $5.35 | $16.43K | 463,615 |
| Darren Sherman See Remarks, Director | Nov 25, 2025 | Tax withholding | −40,340 | $5.35 | $215.82K | 846,157 |
| David P. Hochman See Remarks, Director | Nov 14, 2025 | Buy | +5,000 | $4.07 | $20.35K | 612,822 |
| David P. Hochman See Remarks, Director | Nov 13, 2025 | Tax withholding | −3,283 | $4.18 | $13.72K | 607,822 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Orchestra BioMed's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,986 shares on Sep 15, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Darren Sherman Officer, Director | Nov 2, 2026 | 15,000 | $88.80K | Nov 2, 2026 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Oct 1, 2026 | 15,000 | $94.05K | Oct 1, 2026 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Sep 1, 2026 | 15,000 | $75.30K | Sep 1, 2026 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Aug 3, 2026 | 15,000 | $61.29K | Aug 3, 2026 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Jul 1, 2026 | 15,000 | $64.80K | Jul 1, 2026 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Jun 1, 2026 | 15,000 | $58.05K | Jun 1, 2026 | Restricted Stock Vesting |
| Eric S. Fain Director | Jun 26, 2025 | 2,683 | $8.19K | Jun 26, 2025 | Restricted Stock Vesting |
| Eric S. Fain Director | Sep 10, 2024 | 1,800 | $9.62K | Sep 10, 2024 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Sep 10, 2024 | 6,904 | $36.65K | Sep 10, 2024 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Sep 9, 2024 | 6,804 | $37.32K | Sep 9, 2024 | Restricted Stock Vesting |
| Eric S. Fain Director | Sep 9, 2024 | 1,800 | $9.77K | Sep 9, 2024 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Sep 6, 2024 | 6,819 | $38.51K | Sep 6, 2024 | Restricted Stock Vesting |
| Eric S. Fain Director | Sep 6, 2024 | 2,000 | $11.28K | Sep 6, 2024 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Sep 5, 2024 | 6,961 | $40.71K | Sep 5, 2024 | Restricted Stock Vesting |
| Darren Sherman Officer, Director | Sep 4, 2024 | 6,837 | $41.70K | Sep 4, 2024 | Restricted Stock Vesting |
See a number that looks wrong?